BioSpace News Archive

Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply Logica™ across several previously undrugged targets in the RS portfolio.

Senseonics Holdings, Inc. today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually.

Bionano Genomics, Inc., announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families.

Stryker, one of the world’s leading medical technology companies, unveiled the next-generation of minimally invasive surgical cameras: the 1788 platform.

PharmaEssentia USA Corporation , and MPN Advocacy & Education International, a leading advocacy group dedicated to providing the knowledge, support and resources patients will need as they adjust to living with a myeloproliferative neoplasm (MPN), today announced a new educational initiative for the MPN community called PV&ME.

Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that Dr. Jacob Jacobsen has been appointed President and CEO.

FibroBiologics announced today that Pete O’Heeron, Founder/Chief Executive Officer, and Hamid Khoja Ph.D., Chief Scientific Officer, will be giving company presentations at the upcoming Life Science Intelligence (LSI) Europe ’23 Emerging MedTech Summit September 18-22, 2023; and Cell & Gene Meeting on the Mesa October 10-12, 2023.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) today announced financial results for first quarter fiscal year 2024, which ended July 31, 2023.

Phoenix PharmaLabs, Inc. today announced that in vivo studies demonstrated that the company’s lead compound, PPL-138, reduced symptoms of PTSD and decreased alcohol consumption in a rat model of PTSD/AUD (alcohol abuse disorder).

Pasithea Therapeutics Corp. today announced the final results of its previously announced tender offer to acquire up to 5,714,285 shares of its common stock, par value $0.0001 per share, at a price of $0.70 per share.